Revolution Medicines, Summit Therapeutics Partner to Test Cancer Treatment Combinations

MT Newswires Live06-30

Revolution Medicines (RVMD) and Summit Therapeutics (SMMT) said Monday they have agreed to a clinical collaboration to evaluate the safety and efficacy of each of Revoluntion's clinical-stage inhibitors in combination with Summit's ivonescimab on certain solid tumor types.

Financial terms of the partnership were not disclosed.

Under the terms of the agreement, Summit will supply the drug for clinical research while Revolution will sponsor the studies. Each company will also retain commercial rights to their respective compounds.

The partnership aims to evaluate these combinations on patients with RAS mutant non-small cell lung cancer, pancreatic ductal adenocarcinoma and colorectal cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2547091136?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-30 20:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2547091136","market":"us","top_or_hot":-1,"title":"Revolution Medicines, Summit Therapeutics Partner to Test Cancer Treatment Combinations","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/RVMD\">Revolution Medicines</a> (RVMD) and Summit <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SMMT) said Monday they have agreed to a clinical collaboration to evaluate the safety and efficacy of each of Revoluntion's clinical-stage inhibitors in combination with Summit's ivonescimab on certain solid tumor types.</p><p>Financial terms of the partnership were not disclosed.</p><p>Under the terms of the agreement, Summit will supply the drug for clinical research while Revolution will sponsor the studies. Each company will also retain commercial rights to their respective compounds.</p><p>The partnership aims to evaluate these combinations on patients with RAS mutant non-small cell lung cancer, pancreatic ductal adenocarcinoma and colorectal cancer.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revolution Medicines, Summit Therapeutics Partner to Test Cancer Treatment Combinations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevolution Medicines, Summit Therapeutics Partner to Test Cancer Treatment Combinations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-30 20:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/RVMD\">Revolution Medicines</a> (RVMD) and Summit <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SMMT) said Monday they have agreed to a clinical collaboration to evaluate the safety and efficacy of each of Revoluntion's clinical-stage inhibitors in combination with Summit's ivonescimab on certain solid tumor types.</p><p>Financial terms of the partnership were not disclosed.</p><p>Under the terms of the agreement, Summit will supply the drug for clinical research while Revolution will sponsor the studies. Each company will also retain commercial rights to their respective compounds.</p><p>The partnership aims to evaluate these combinations on patients with RAS mutant non-small cell lung cancer, pancreatic ductal adenocarcinoma and colorectal cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDCO","symbol_name":"麦迪逊医药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2547091136","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547091136","pubTimestamp":1751286920,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Revolution Medicines  and Summit Therapeutics  said Monday they have agreed to a clinical collaboration to evaluate the safety and efficacy of each of Revoluntion's clinical-stage inhibitors in combination with Summit's ivonescimab on certain solid tumor types.Financial terms of the partnership were not disclosed.Under the terms of the agreement, Summit will supply the drug for clinical research while Revolution will sponsor the studies. Each company will also retain commercial rights to their respective compounds.The partnership aims to evaluate these combinations on patients with RAS mutant non-small cell lung cancer, pancreatic ductal adenocarcinoma and colorectal cancer.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDCO":"麦迪逊医药","BK4007":"制药","BK4211":"区域性银行","SMMT":"Summit Therapeutics PLC","LENZ":"Therapeutics","BK4539":"次新股","RVMD":"Revolution Medicines, Inc.","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4139":"生物科技","SMMF":"Summit Financial Group"},"translate_title":"Revolution Medicines与Summit Therapeutics合作测试癌症治疗组合","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDCO":1,"SMMF":1,"RVMD":1,"SMMT":0.9,"LENZ":1},"content_text":"Revolution Medicines (RVMD) and Summit Therapeutics (SMMT) said Monday they have agreed to a clinical collaboration to evaluate the safety and efficacy of each of Revoluntion's clinical-stage inhibitors in combination with Summit's ivonescimab on certain solid tumor types.Financial terms of the partnership were not disclosed.Under the terms of the agreement, Summit will supply the drug for clinical research while Revolution will sponsor the studies. Each company will also retain commercial rights to their respective compounds.The partnership aims to evaluate these combinations on patients with RAS mutant non-small cell lung cancer, pancreatic ductal adenocarcinoma and colorectal cancer.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2547091136","isCrawlerRequest":true}